Top

News & Events

Client News

Client News

Abcam and the Loulou Foundation partner to develop key research tools for CDKL5 deficiency disorder

London and Cambridge, UK - Today, Abcam, a global innovator in life science reagents and tools, and the Loulou Foundation, a private UK-based foundation dedicated to the development of therapeutics for CDKL5 Deficiency Disorder, announced a research collaboration to discover new tools to advance research in this area of high unmet medical need.

Read more »

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

Stevenage, UK – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the first milestone has successfully been achieved under Autifony’s option agreement with Boehringer Ingelheim. As announced previously, Boehringer Ingelheim acquired an exclusive option to purchase Autifony’s Kv3.1/3.2 positive modulator platform in December 2017. Further details of the milestone were not disclosed.

Read more »

Clinigen Half Year trading update

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides an unaudited trading update for the six months ended 31 December 2018.

Read more »

Clinigen extends exclusive European clinical trial sourcing and supply agreement with Accord Healthcare

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Trial Service (‘CTS’) business has extended its exclusive European clinical trial supply agreement with Accord Healthcare (‘Accord’). Clinigen is also offering pharma companies an ‘on demand’ service to Accord’s products, a first for the industry.

Read more »

Crescendo Biologics announces Humabody® evaluation in CAR-T by Takeda

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda) is planning to evaluate the application of recently licensed Humabodies from Crescendo for the development of novel CAR-T therapeutics.

Read more »

US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies

Munich, Germany – Immatics, a leading company in the field of cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued the 100th patent to Immatics.

Read more »

Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology

Ghent, Belgium – Confo Therapeutics, an emerging drug discovery company, today announces that it has entered into an agreement with VIB, a life sciences research institute in Flanders, Belgium, for an exclusive, worldwide license to VIB’s ‘Megabody’ technology.

Read more »

HOOKIPA Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapies targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has achieved its first research milestone in its collaboration and license agreement with Gilead Sciences, Inc. (“Gilead”). The agreement, which was entered into in June 2018, grants Gilead exclusive rights to HOOKIPA’s TheraT® and VaxWave® investigational arenavirus-based immunization technologies for the development of immunotherapies against hepatitis B virus (HBV) and human immunodeficiency virus (HIV).

Read more »

Immatics: Nature publication reports first-in-human trial for a personalized cancer immunotherapy

Tuebingen, Germany – The prospect of an actively personalized approach to the treatment of cancer has moved a step closer with the recent publication in Nature of data from the phase 1 study GAPVAC-101, testing a novel therapeutic concept tailored to specific characteristics of patients’ individual tumors and immune systems. For the first time, the feasibility of such a highly personalized form of immunotherapy has been exemplified in a multi-center, multi-national clinical setting.

Read more »

HOOKIPA Doses First Patient in a Phase 2 Clinical Trial of Prophylactic Vaccine Candidate HB-101 against Cytomegalovirus

New York, US and Vienna, Austria, December - HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapies targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has dosed the first patient in its randomized, placebo-controlled, Phase 2 clinical trial to evaluate the safety and efficacy of HB-101, a bivalent prophylactic vaccine for cytomegalovirus (CMV), in CMV-negative patients awaiting kidney transplantation from living CMV-positive donors.

Read more »

Imugene Meets Endpoints in Phase 1b Gastric Cancer Immuno-oncology Trial

SYDNEY, Australia: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced meeting study endpoints and positive top-line results from the Phase 1b study of its HER-Vaxx gastric cancer vaccine in patients expressing the HER2 target protein.

Read more »

Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia

Naarden, The Netherlands, and Munich, Germany – Forbion today announces that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia.

Read more »

Uncertainty for pharma and biotech in 2019 as sector stumbles at the end of 2018

LONDON, BOSTON, TOKYO – The downturn seen in the pharma and biotech sectors in the past few months of 2018 looks set to continue into 2019, with investors in the industry likely to become more cautious. According to Vantage, the independent editorial arm of Evaluate Ltd., the plus side of this could be a rallying M&A market as valuations drop, but financing will be harder to come by for those without the data to back their ideas.

Read more »

Interim Durability Analysis of PTX-200 in Breast Cancer Responders Demonstrates No Disease Progression

Melbourne, Australia: Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX; Prescient) today announced interim durability data on the PTX-200 study in HER2 negative locally advanced breast cancer. Follow-up studies have determined that none of the five responders in the Phase 2 component of the trial have had disease progression to date.

Read more »

Valneva and HOOKIPA Sign a Collaboration and Manufacturing Agreement

Saint-Herblain, France, and Vienna, Austria – Valneva Sweden AB, the Swedish subsidiary of Valneva SE (“Valneva”), and HOOKIPA Pharma Inc. (“HOOKIPA”) today announced that they have entered into a three-year collaboration and manufacturing agreement.

Read more »

SpeeDx Receives CE-IVD Mark for ResistancePlus® GC

SYDNEY, AUSTRALIA - SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted infection (STI) N. gonorrhoeae (GC) and sequences in the gyrA gene of the bacteria associated with susceptibility to ciprofloxacin, a previously used front-line antibiotic treatment.

Read more »

Confo Therapeutics Appoints Frank Landolt as its Chief Counsel Legal & Intellectual Property

Ghent, Belgium - Confo Therapeutics, an emerging drug discovery company, today announces the appointment of Frank Landolt as its Chief Counsel Legal & IP, effective from 1 January 2019. Frank is joining the Company from Ablynx, now a wholly owned Sanofi company, where he was Vice President Legal & IP and a member of the Executive Committee.

Read more »

MISSION THERAPEUTICS: Dr Nick Edmunds Appointed to VP, Head of DUB Discovery

CAMBRIDGE, UK – Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Nick Edmunds as Vice President, Head of DUB Discovery, with immediate effect.

Read more »

Feedback plc - Final Results for year ended 31 May 2018: Invoiced sales up 51% following significant contract, investment and restructuring

Cambridge, UK - Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces its full year results for the year to 31 May 2018.

Read more »

Forbion Appoints Dr. Carlo Incerti as Operating Partner

Naarden, The Netherlands, and Munich, Germany – Forbion, a leading European life science venture capital firm, today announces that Carlo Incerti, M.D., will be joining Forbion as Operating Partner, effective 1 January 2019.

Read more »

HOOKIPA and DarwinHealth Enter into a Research Collaboration and License Agreement to Discover and Prioritize Novel Immunogenic, Tumor-Specific Cryptic Antigens

New York, US and Vienna, Austria – HOOKIPA Pharma Inc. (“HOOKIPA”), a clinical stage biopharmaceutical company developing a new class of immuno-therapeutics targeting infectious diseases and cancers based on its proprietary technology platform, announced today that it entered into a research collaboration and license agreement with DarwinHealth to develop novel immunotherapies based on the systematic discovery and prioritization of the next generation of immunogenic, tumor-specific cryptic antigens.  DarwinHealth is a precision-focused cancer medicine company, utilizing systems-biology derived algorithms to identify appropriate therapies for cancer patients and to systematically discover and prioritize the next generation of immunogenic, tumor-specific antigens.

Read more »

UCL Spin-out Engitix Closes £5m Financing to Progress Liver Disease and Pancreatic Cancer Drug Discovery Platform and Pipeline

London, UK – Engitix Ltd, a company pioneering the development of both tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and improving the drug discovery process, today announces it has closed a £5 million Series A financing, led by a private investor.

Read more »

Immune Regulation announces positive results from Phase 1 clinical trial of PIN201104

Stevenage, UK - Immune Regulation Ltd. (‘Immune Regulation’ or the ‘Company’, formerly known as Peptinnovate), a biopharmaceutical company developing “first in class” immune-resetting therapies for asthma and other inflammatory diseases, announces positive results from a Phase 1 study of its lead compound PIN201104 (‘1104).

Read more »

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Stevenage, UK - Peptinnovate Ltd (‘Peptinnovate’ or the ‘Company’, a biotechnology company developing novel immune modulators for immunological and inflammatory diseases, announces that it has changed its corporate name from Peptinnovate to Immune Regulation with immediate effect. The new website for Immune Regulation is www.immuneregulation.com.

Read more »

SkinBioTherapeutics plc: Commencement of final phase of human studies

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”), a life science company focused on skin health, announces the commencement of the third and final phases of its human study and provides a summary of key scientific and commercial milestones achieved so far in 2018.

Read more »